Jefferies downgraded Biogen from Buy to Hold, setting a new price target of $180, down from $250. Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition.

Private Medicare plans must cover Biogen's ALS drug, US agency says Healthcare & Pharmaceuticalscategory· December 13, 2024 Corcept Therapeutics said on Wednesday its experimental drug failed to ...

Dec 12 (Reuters) - The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen's ... pay a settlement or face civil charges ...

Investing.com -- Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm slashed its price target for the stock to $180 from $250 ...

Biogen's Earnings Growth And 9.9% ROE On the face of it, Biogen's ROE is not much to talk about. We then compared the company's ROE to the broader industry and were disappointed to see that the ...

What risks does Biogen face from pipeline setbacks and increasing competition? Recent pipeline setbacks, such as the discontinuation of SAGE-324, have increased the pressure on Biogen's remaining ...

Biogen BIIB stock has declined 21.4% in the past three months against a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart ...

The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS ...